Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Capital Employed (2016 - 2026)

Myriad Genetics has reported Return on Capital Employed over the past 15 years, most recently at 66.35% for Q4 2025.

  • Quarterly Return on Capital Employed fell 5249.0% to 66.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.35% through Dec 2025, down 5249.0% year-over-year, with the annual reading at 52.8% for FY2025, 3942.0% down from the prior year.
  • Return on Capital Employed was 66.35% for Q4 2025 at Myriad Genetics, up from 75.81% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 12.15% in Q3 2022 and troughed at 75.81% in Q3 2025.
  • The 5-year median for Return on Capital Employed is 17.52% (2021), against an average of 25.86%.
  • Year-over-year, Return on Capital Employed soared 1655bps in 2024 and then plummeted -6334bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 16.95% in 2021, then rose by 22bps to 13.16% in 2022, then plummeted by -97bps to 25.95% in 2023, then soared by 47bps to 13.86% in 2024, then tumbled by -379bps to 66.35% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Return on Capital Employed are 66.35% (Q4 2025), 75.81% (Q3 2025), and 65.0% (Q2 2025).